Potent and selective inhibitors of Akt kinases slow the progress of tumors <i>in vivo</i>
Yan Luo, Vincent L. Giranda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keith W. Woods(Abbott Fund), Ron de Jong(Takeda (United States)), Phong Nguyen(Children's Medical Center), Vered Klinghofer(Abbott Fund), Yan Shi(Abbott Fund), Vincent S. Stoll, Jennifer J. Bouska(Abbott Fund), Tilman Oltersdorf(Harvard University), Emily E. Gramling-Evans, Anatol Oleksijew(Abbott Fund), Richard A. Smith(University of Utah), Jessica A. Powlas, Ran Guan(Abbott Fund), Amanda K. Mika(Abbott Fund), Tongmei Li, Eric F. Johnson(Pfizer (United States)), Qun Li, Xuesong Liu(Tianjin Institute of Pharmaceutical Research (China)), Sheela A. Thomas(Abbott Fund), Alexander R. Shoemaker(Abbott Fund), Thomas McGonigal(Abbott Fund), Saul H. Rosenberg(Abbott Fund), Edward K. Han(Abbott Fund), Mulugeta Mamo, Michael J. Mitten(Abbott Fund), Bradley A. Zinker(Abbott (United States))
Cited by 244
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
|Nature|2007|1.6k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k